The clinical outcomes of chronic hepatitis C in South Korea

A prospective, multicenter cohort study

Kyeong Sam Ok, MDa, Sook-Hyang Jeong, MD, PhDb,∗, Eun Sun Jang, MDd, Young Seok Kim, MDd, Youn Jae Lee, MDe, In Hee Kim, MDf, Sung Bum Cho, MDe, Si Hyun Bae, MDf, Han Chu Lee, MDg

Abstract

This prospective cohort study aimed to elucidate the clinical outcome and its related factors of chronic hepatitis C in a hepatitis B-dominant Asian region. From January 2007 to October 2012, 382 patients with chronic hepatitis C without liver cirrhosis were prospectively enrolled at 6 university hospitals, and regularly followed until Apr 2014 to identify the development of liver cirrhosis, decompensated cirrhosis, hepatocellular carcinoma (HCC), and overall survival. During the median follow-up of 39.0 months (range 18.0–81.0 months), liver cirrhosis, hepatic decompensation, and HCC developed in 42 patients (11.0%), 4 patients (1.0%), and 12 patients (3.1%), respectively. The cumulative probability of development of cirrhosis at 3 years and at 5 years was 9.6% and 16.7%, respectively. That of HCC at 3 and 5 years was 1.6% and 4.5%, respectively. The 3-year and 5-year overall survival rate was 99.7% and 96.0%, respectively. Pegylated interferon-based antiviral therapy was undertaken in 237 patients (62.0%) with a sustained virologic response (SVR) rate of 74.3%. The factors related to the overall clinical outcomes were age ≥55 years (HR 2.924, P = 0.016), platelet counts <150 × 109/L (HR 3.195, P = 0.007), and the achievement of SVR (HR 0.254, P = 0.002).

The clinical outcomes of this Korean chronic hepatitis C cohort were modest with minimal mortality, but significant disease progression occurred in the patients with old age, low platelet, and non-SVR after interferon-based antiviral treatment or no treatment, suggesting priority for direct acting antiviral therapy.

Abbreviations: AFP = alpha-fetoprotein, ALT = alanine aminotransferase, APRI = aspartate aminotransferase-to-platelet ratio index, AST = aspartate aminotransferase, BMI = body mass index, CI = confidence interval, DAA = direct acting antiviral therapy, EVR = early virologic response, FIB-4 index = fibrosis-4 index, GGT = gamma glutamyltransferase, HBsAg = hepatitis B surface antigen, HBV = hepatitis B virus, HCC = hepatocellular carcinoma, HCV = hepatitis C virus, HCV RNA = hepatitis C virus ribonucleic acid, HR = hazard ratio, INR = international normalized ratio, pegIFN-α = pegylated interferon alpha, PR = pegIFN-α and ribavirin, RVR = rapid virologic response, SVR = sustained virologic response.

Keywords: hepatitis C virus, hepatocellular carcinoma, liver cirrhosis, survival, sustained virologic response

1. Introduction

The global prevalence of hepatitis C virus (HCV) infection has increased from 2.3% to 2.8% between 1990 and 2005.[1] An estimate of the prevalence of anti-HCV among Koreans adults over 20 years old was 0.78% in 2009, and 10% to 15% of HCC is attributable to HCV infection in Korea.[2,3] Although the natural history of HCV infection is highly variable according to study population and method, an estimated 15% to 30% of chronic hepatitis patients have progression to cirrhosis over the ensuing 3 decades.[4,5] Therefore, HCV infection is the leading cause of liver cirrhosis and hepatocellular carcinoma (HCC) resulting in a major global health burden.[6]

Antiviral therapy with pegylated interferon alpha (pegIFN-α) and ribavirin (PR therapy) was the standard of care for all HCV genotypes during the last decade.[7–9] Thus, clinical outcomes rather than the natural history of chronic hepatitis C are recently

* Correspondence: Sook-Hyang Jeong, Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, 82, Gunim-ro 173 Beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, Republic of Korea (e-mail: jsh@snubh.org).

Copyright © 2016 the Author(s). Published by Wolters Kluwer Health, Inc. All rights reserved.

This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially.

Medicine (2016) 95(35):e4594

Received: 7 April 2016 / Received in final form: 1 July 2016 / Accepted: 24 July 2016

http://dx.doi.org/10.1097/MD.0000000000004594
reported including the risk of HCC development and overall mortality with various rates of antiviral treatment.\textsuperscript{10–14} A clinical outcome study is important in the era of direct acting antiviral therapy (DAA), because the high cost of drugs can be justified by cost-effectiveness based on the clinical outcomes, especially in many resource-constrained regions. Several studies, performed mostly in Western countries, predicted that HCV-related morbidity and mortality may increase in the next decade, even though DAA is available.\textsuperscript{15–17} However, very little is known about the clinical outcomes of chronic hepatitis C in East Asian countries where hepatitis B virus (HBV) is prevalent rather than HCV.\textsuperscript{18,19} Moreover, the epidemiological features and host genetic background of chronic hepatitis C patients in the Asian region are different from those of Western countries.\textsuperscript{18}

A prospective, multicenter HCV cohort in South Korea was established and its cohort profile was reported previously.\textsuperscript{19} Using those cohort data, this study aimed to elucidate the incidence of liver cirrhosis, HCC, and all-cause mortality in chronic hepatitis C patients, and to identify the risk factors related to those clinical outcomes. To the best of our knowledge, this is the first prospective cohort study in a real-world clinical practice that observed the major outcomes of chronic hepatitis C patients in an HBV-prevalent Asian region.

2. Materials and methods

2.1. Study design and patients

In the prospective, multicenter Korea HCV cohort, 1065 patients with HCV ribonucleic acid (RNA) positivity > 6 months were enrolled at 6 university hospitals from January 2007 to October 2012. Among them, 378 patients who were initially given diagnosis of liver cirrhosis or HCC, 154 patients who had previously received antiviral therapy before enrollment, and 151 patients followed less than 18 months, were excluded from this study. Therefore, 382 treatment-naive, chronic hepatitis C patients who were followed > 18 months were the subjects of this study. Patients coinfected with HBV, defined as hepatitis B surface antigen (HBsAg) positivity, were included, because coinfection with HBV and HCV may have a significant impact on the clinical outcomes of HCV in HBV-endemic areas. All patients provided written informed consent, and the study was approved by the Institutional Review Board of each hospital. The study protocol was consistent with the ethical guidelines of the 1975 Declaration of Helsinki.

2.2. Questionnaire survey and clinical data collection at enrollment

At enrollment, a trained research coordinator at each hospital interviewed the patient using a standardized questionnaire, which included socio-demographics (age, gender, education, and occupation), health behavior (smoking and drinking), accompanying diseases (cancer, psychiatric disease, diabetes, kidney disease, cerebro-, and cardiovascular diseases), and their lifetime experience with theoretical risk factors for HCV infection (blood transfusion, hemodialysis, intravenous drug use, tattooing, piercing, needle stick injury, acupuncture, dental procedures, diagnostic endoscopy, surgery, family history of HCV-related liver disease, and number of sexual partners).

Each subject underwent blood biochemical tests such as serum HCV RNA level, HCV genotype, HBsAg, anti-hepatitis B virus surface antibody (anti-HBs), complete blood cell count, aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin, gamma glutamyl transferase (GGT), albumin, creatinine, and alpha fetoprotein (AFP), and radiological examinations such as ultrasonography or computed tomography (CT). Completed questionnaires and clinical data were collected and entered into the electronic case report form (CRF) at the Korean HCV cohort study group homepage (http://www.hcvcohort.or.kr).

2.3. Follow-up and determination of clinical outcomes

The subject patients were prospectively followed at least every 6 months at each institution by medical examinations or phone call until April 2014. The median follow-up duration was 39.0 months (range 18.0–81.0). Standard antiviral therapy with pegIFN-α and ribavirin was administered to the patients in whom it was indicated according to the attending physicians’ decision at each site. During the study period, no DAA was available in Korea except in clinical trial settings, and 28 patients participated in the clinical trials including 1st generation DAA with PR therapy. Until April 2014, the individual patient’s status was determined as remaining as chronic hepatitis, changed to cirrhosis (compensated or decompensated), development of HCC or mortality. Cirrhosis of the liver was defined as histological results in liver biopsy, or compatible radiological findings accompanied by clinical features indicative of portal hypertension, such as thrombocytopenia (a platelet count < 10\(^{5}\)/L), gastroesophageal varices, or splenomegaly. HCC was diagnosed by histological examination or by typical radiographic findings consisting of arterial enhancement and venous wash-out on contrast-enhanced (CT) or magnetic resonance imaging (MRI) of hepatic nodules. The composite disease progression was defined as development of liver cirrhosis, hepatic decompensation (ascites, spontaneous bacterial peritonitis, variceal bleeding, and hepatic encephalopathy), HCC, death, or liver transplantation.

As a simple and validated serum marker of hepatic fibrosis, AST-platelet ratio index (APRI) ([AST/upper normal limit] × 100/platelet [10\(^{9}\)/L]) and FIB-4 (age [years] × AST [IU/L]/platelets [10\(^{9}\)/L] × [ALT [IU/L]]\(^{1/2}\)) were calculated for each patient at enrollment and at last follow-up. As an indirect marker of fibrosis progression, the change of FIB-4 index/year (delta FIB-4) was calculated, in which delta FIB-4 was calculated as [(FIB-4 at last follow-up) – (FIB-4 at enrollment)]/follow-up years.

2.4. Statistical analysis

Categorical variables were compared with the \(\chi^2\) test, and continuous variables were compared with Student\(\text{t}\) test. The cumulative incidence rates of liver cirrhosis, HCC, all-cause mortality, and composite disease progression were calculated and plotted using the Kaplan–Meier method. Differences of the incidence rate between subgroups were analyzed using the log-rank test. To identify the factors associated with disease progression, multivariate analysis was performed using Cox regression analysis for variables with \(P\) values of < 0.05 on the univariate analysis. A \(P\) value of < 0.05 was considered to indicate a statistically significant difference. SPSS version 21.0 (IBM SPSS Inc, Chicago, IL) was used for all statistical analyses except incidence rate analysis, for which STATA 13 (StataCorp LP, College Station, TX) was used.

3. Results

3.1. Patient characteristics and antiviral treatment

Baseline characteristics of the 382 patients with chronic hepatitis C are summarized in Table 1, showing a mean age of 54.8 years,
Table 1
Comparison of clinical features between treated group and nontreated group using pegylated interferon and ribavirin therapy in chronic hepatitis C patients.

| Variables                                        | Total n = 382 (%) | Treated group n = 237 (%) | Nontreated group n = 145 (%) | P value |
|--------------------------------------------------|-------------------|---------------------------|-------------------------------|---------|
| Age at entry, y†                                 | 54.8±12.7         | 50.6±10.8                 | 61.6±12.5                     | <0.001† |
| Male*                                            | 166 (43.5)        | 105 (44.3)                | 61 (42.1)                     | 0.669   |
| BMI (kg/m²)†                                     | 23.3±3.9          | 23.2±4.0                  | 23.5±3.7                      | 0.473   |
| Obesity (BMI >25 kg/m²)‡                         | 110 (29.6)        | 64 (29.1)                 | 46 (30.5)                     | 0.776   |
| Current alcohol intake‡                          | 131 (37.8)        | 96 (44.9)                 | 35 (26.3)                     | 0.001†  |
| Alcohol intake amount‡                           |                   |                           |                               | 0.042‡  |
| <20 g/d                                          | 279 (79.5)        | 165 (76.0)                | 114 (85.1)                    |         |
| ≥20 g/d                                          | 72 (20.5)         | 52 (24.0)                 | 20 (14.9)                     |         |
| Current smoker at enrollment‡                   | 127 (37.0)        | 87 (41.4)                 | 40 (3.1)                      | 0.034†  |
| Smoking amount‡                                  |                   |                           |                               | 0.020†  |
| <20 pack-years                                   | 266 (69.0)        | 165 (81.3)                | 101 (78.9)                    |         |
| ≥20 pack-years                                   | 65 (19.6)         | 38 (18.7)                 | 27 (21.1)                     |         |
| Employed state‡                                  | 181 (50.0)        | 125 (56.3)                | 56 (40.0)                     | 0.003‡  |
| Follow-up duration, months                       |                   |                           |                               |         |
| Mean±SD†                                         | 41.9±16.2         | 38.8±17.1                 | 38.6±16.5                     | 0.761   |
| Median (range)                                   | 39.0 (18.0–81.0)  | 39.0 (18–81)              | 39.0 (18–80)                  | 0.710   |
| Diabetes mellitus‡                               | 52 (13.9)         | 29 (12.2)                 | 22 (15.3)                     | 0.398   |
| Serologic findings‡                              |                   |                           |                               |         |
| HBV coinfection‡                                  | 13 (3.9)          | 10 (4.7)                  | 3 (2.4)                       | 0.387   |
| HCV RNA titer >400,000 IU/mL‡                    | 220 (60.9)        | 140 (61.1)                | 80 (60.6)                     | 0.921   |
| HCV genotype‡                                    |                   |                           |                               | 0.153   |
| 1                                               | 179 (51.0)        | 109 (48.2)                | 70 (56.0)                     |         |
| 2                                               | 164 (46.7)        | 111 (49.1)                | 53 (42.4)                     |         |
| 3/4/6                                           | 2 (0.6)/1 (0.3)/5 (1.4) | 1 (0.8)/0 /1 (0.8)   | 1 (0.4)/1 (0.4)/4 (1.8)      |         |
| Laboratory findings‡                             |                   |                           |                               |         |
| Platelet (×10³/µL)†                              | 188.4±60.9        | 188.6±61.3                | 188.0±60.4                    | 0.938   |
| AST (IU/L)‡                                      | 78.9±141.3        | 81.2±114.0                | 72.6±177.2                    | 0.562   |
| ALT (IU/L)‡                                      | 103.8±303.9       | 102.6±146.5               | 105.8±456.5                   | 0.921   |
| GGT (IU/L)‡                                      | 69.4±86.2         | 72.5±84.6                 | 64.5±88.7                     | 0.442   |
| Total bilirubin (mg/dL)‡                         | 0.88±0.53         | 0.85±0.37                 | 0.93±0.72                     | 0.228   |
| Albumin (g/dL)‡                                   | 4.25±0.37         | 4.27±0.36                 | 4.20±0.39                     | 0.077   |
| Prothrombin time, INR‡                           | 1.23±4.87         | 1.38±6.07                 | 0.96±0.39                     | 0.508   |
| APRI                                              | 6.97±10.85        | 7.78±13.12                | 5.93±6.81                     | 0.169   |
| FB-4 index‡                                      | 1.24±2.92         | 1.27±2.12                 | 1.20±0.88                     | 0.825   |
| Liver biopsy performed‡                          | 69 (18.1)         | 62 (26.2)                 | 7 (4.8)                       |         |
| Potential Risk factors for HCV infection‡        |                   |                           |                               |         |
| Intravenous drug use‡                             | 27 (7.2)          | 18 (7.8)                  | 9 (6.3)                       | 0.582   |
| Needle stick injury‡                              | 106 (28.1)        | 60 (27.9)                 | 46 (31.7)                     | 0.079   |
| Tattooing‡                                       | 33 (9.0)          | 21 (10.3)                 | 12 (8.3)                      | 0.757   |
| Piercing‡                                        | 163 (43.5)        | 103 (44.4)                | 60 (42.0)                     | 0.644   |
| Operation history‡                               | 151 (40.2)        | 103 (44.4)                | 48 (33.3)                     | 0.033‡  |
| No. of sexual partners ≥3‡                       | 180 (48.0)        | 108 (46.6)                | 72 (50.3)                     | 0.475   |
| Treatment regimen‡                               | 48 (16.4)         | 28 (16.4)                 | 20 (14.4)                     | 0.997   |
| Pegylated interferon alpha and ribavirin (PR) combination‡ | 209 (88.2) |                                               |                               |         |
| Clinical trial including PR†                    | 28 (11.8)         |                                               |                               |         |
| SVR†                                             | 168 (74.3)        |                                               |                               |         |
| RVR†                                             | 129 (64.2)        |                                               |                               |         |
| EVR (complete/partial)†                          | 177 (81.2)        |                                               |                               |         |
| Relapse‡                                         | 19 (5.0)          |                                               |                               |         |

P values are for the comparison between groups. 

APP = alpha-fetoprotein, ALT = alanine aminotransferase, APRI = aspartate aminotransferase-to-platelet ratio index, AST = aspartate aminotransferase, BMI = body mass index, EVR = early virologic response, HCV = hepatitis C virus, INR = international normalized ratio, PR = pegylated interferon alpha and ribavirin combination therapy with standard duration of treatment according to HCV genotype or on-treatment response, RFA = ribonucleic acid, RVR = rapid virologic response, SVR = sustained virologic response.

† P < 0.05.
‡ Mean±standard deviation.
§ n (percent).
and male gender in 43.5%. Mean follow-up duration was 41.9 months. In total, 179 patients (51.0%) were infected with genotype 1 HCV, and 164 (46.7%) were infected with genotype 2. The mean ALT level was 103.8 IU/L, and the mean albumin level was 4.25 g/dL. Liver biopsy was performed only in 18.1% of the subjects, and our diagnostic criteria for liver cirrhosis was a clinical one with no available liver elastography results. The mean APRI was 1.24, and the mean FIB-4 index was 2.68. A FIB-4 index higher than 3.25 indicating advanced fibrosis (a Metavir fibrosis stage of F3 to F4) was found in 29.5% of the patients at enrollment. HBV coinfection was found in 3.9%, which was similar to that of the general population in South Korea.

A total 237 patients (62.0%) underwent antiviral treatment consisting of pegIFN-α and ribavirin combination as the standard PR therapy (n = 209), or clinical trials including 1st generation DAA, in addition to PR therapy (n = 28). Sustained virologic response (SVR) was achieved in 168 patients (74.3%) among the 237 treated patients. The achievement rates of SVR in genotype 1 and the other genotype were 64.2% and 85.5%, respectively (P = 0.001). The SVR rate of the patients with PR therapy was 78.9%, and that of the patients participating in clinical trials was 83.3% (P = 0.655, unpublished data). The comparative analysis of clinical features between 237 patients who received antiviral treatment and 145 patients who did not undertake the therapy is summarized in Table 1. The treated group showed significantly younger patients with a higher proportion of current alcohol drinkers, current smokers, in an employed state, and in a lower range of FIB-4 index. Liver biopsy was more frequently performed in the treated group than the nontreated group. Interestingly, the mean delta FIB-4/year during the study period was −0.27 in the treated group, while it was +0.35 in the nontreated group.

3.2. Incidence of liver cirrhosis, HCC, and mortality in chronic hepatitis C patients

Of the 382 patients, 42 (11.0%) patients developed liver cirrhosis during the mean follow-up period of 41.9 months. The estimated incidence of cirrhosis development was 33 per 1000 person-years (95% CI, 24.9–45.6). The cumulative probability of development of cirrhosis at 3 years and at 5 years was 9.6% and 16.7%, respectively. None progressed to decompensated cirrhosis as the first clinical event.

HCC developed in 12 patients (3.1%), and the estimated incidence rate of HCC was 9.2 (95% CI, 5.2–16.1) per 1000 person-years for chronic hepatitis patients. The cumulative probability of HCC development at 3 and 5 years was 1.6% and 4.5%, respectively (Fig. 1A). The estimated annual incidence of HCC development was 0.9% in the first 5 years from entry.

Composite disease progression occurred in 50 patients (13.1%); 42 patients developed compensated cirrhosis, 12 patients developed HCC, and 4 patients died. The estimated incidence of the composite disease progression was 40.6 (95% CI, 30.8–53.6) per 1000 person-years for chronic hepatitis C.
patients. The cumulative probabilities of the composite disease progression at 3 and 5 years were 10.9% and 21.3%, respectively (Fig. 1B). The estimated annual incidence of the composite disease progression was 4.2%.

There were 4 cases of mortality (1.0%) during the follow-up period. The cause of death was HCC progression in 1 case, and extrahepatic causes in the other 3 cases (cerebral infarction, traumatic subdural hemorrhage, and lung cancer). There were no patients who received liver transplantation. The estimated incidence rate of overall mortality was 3.0 (95% CI, 1.1–7.9) per 1000 person-years. The cumulative probability of overall survival was 99.7% and 96% at 3 and 5 years (Fig. 1C).

3.3. Factors associated with development of HCC and composite disease progression

The univariate analysis of the factors related to HCC development showed that current alcohol intake, platelet count, serum level of albumin, GGT and AFP level, and achievement of SVR were significant factors. On multivariate analysis, albumin ≥3.5 g/dL (hazard ratio [HR] = 0.061, 95% CI = 0.006–0.395, \( P = 0.016 \)) and the achievement of SVR (HR = 0.061, CI = 0.007–0.510, \( P = 0.010 \)) were independent factors for HCC development (Table 2).

The univariate analysis of the composite disease progression showed that age, employment state, diabetes, albumin, GGT, platelet count, achievement of SVR, and FIB-4 score were significantly related factors. Of these, age <55 years (HR = 0.269, 95% CI = 0.142–0.821, \( P = 0.016 \)), high (≥150 \( \times \) 10^9/L) platelet count (HR = 0.313, CI = 0.134–0.733, \( P = 0.007 \)) and the achievement of SVR (HR = 0.254, CI = 0.108–0.593, \( P = 0.002 \)) were independent factors for the composite disease progression on multivariate analysis (Table 3).

According to antiviral treatment and SVR status, the probability of composite disease progression and HCC development are shown in Fig. 2. The poorest outcome was in the group of patients who failed virologic clearance after antiviral therapy (non-SVR group), followed by the group of treatment-naive

---

Table 2
Univariate and multivariate analysis of factors associated with HCC development.

| Variable               | Univariate analysis | Multivariate analysis |
|------------------------|---------------------|-----------------------|
|                        | HR (95% CI)         | \( P \) value         | HR (95% CI)         | \( P \) value         |
| Age at entry, y        |                     |                       |                     |                       |
| <55                    |                     |                       |                     |                       |
| ≥55                    | 3.395 (0.847–11.638) | 0.065                 |                       |                       |
| Gender                 |                     |                       |                     |                       |
| Female                 | 0.565 (0.179–1.781)  | 0.330                 |                       |                       |
| Male                   | 1.899 (0.602–5.987)  | 0.274                 |                       |                       |
| BMI                    | 4.382 (1.130–16.99)  | 0.033^                |                       |                       |
| <25 kg/m^2             |                     |                       |                     |                       |
| ≥25 kg/m^2             | 0.625 (0.128–3.047)  | 0.561                 |                       |                       |
| Alcohol intake         | 0.910 (0.240–5.020)  | 0.904                 |                       |                       |
| No or former           | 3.791 (0.818–17.57)  | 0.089                 |                       |                       |
| Yes                    | 0.120 (0.015–0.976)  | 0.047*                | 0.061 (0.006–0.595)  | 0.016^                |
| Diabetes               | 0.153 (0.035–0.661)  | 0.012^                |                       |                       |
| No                     | 0.206 (0.060–0.708)  | 0.012^                |                       |                       |
| Yes                    | 7.442 (1.842–30.06)  | 0.005^                |                       |                       |
| HCV genotype           | 0.054 (0.006–0.448)  | 0.007^                | 0.061 (0.007–0.510)  | 0.010^                |
| Non-1                  | 0.120 (0.015–0.976)  | 0.047*                |                       |                       |
| 1                      | 0.153 (0.035–0.661)  | 0.012^                |                       |                       |
| Albumin                | 0.206 (0.060–0.708)  | 0.012^                |                       |                       |
| <3.5 g/dL              | 0.054 (0.006–0.448)  | 0.007^                |                       |                       |
| ≥3.5 g/dL              | 0.061 (0.007–0.510)  | 0.010^                |                       |                       |
| GGT                    | 0.101 (0.007–0.510)  | 0.010^                |                       |                       |
| <70 IU/L               | 7.442 (1.842–30.06)  | 0.005^                |                       |                       |
| ≥70 IU/L               | 0.054 (0.006–0.448)  | 0.007^                |                       |                       |
| Platelet               | 0.120 (0.015–0.976)  | 0.047*                | 0.061 (0.006–0.595)  | 0.016^                |
| <150 \( \times \) 10^9/L | 0.153 (0.035–0.661)  | 0.012^                |                       |                       |
| ≥150 \( \times \) 10^9/L | 0.206 (0.060–0.708)  | 0.012^                |                       |                       |
| AFP                    | 7.442 (1.842–30.06)  | 0.005^                |                       |                       |
| <7 mg/mL               | 0.054 (0.006–0.448)  | 0.007^                |                       |                       |
| ≥7 mg/mL               | 0.061 (0.007–0.510)  | 0.010^                |                       |                       |
| SVR                    | 0.054 (0.006–0.448)  | 0.007^                |                       |                       |

*\( P \) values are for the comparison between groups.
AFP = alpha-fetoprotein, BMI = body mass index, GGT = gamma glutamyl transferase, HCV = hepatitis C virus, SVR = sustained virologic response.

\* \( P < 0.05 \).

According to the Cox proportional hazard model.
patients (naive group), while the best outcome was seen in the group of patients who achieved SVR (SVR group).

4. Discussion

This prospective study demonstrated clinical outcomes of chronic hepatitis C in a Korean cohort for the first time. The 5-year overall survival rate of 382 chronic hepatitis C patients was 96%, and the liver-related death occurred in only 1 of 4 mortality cases. The cumulative probability of the composite disease progression including development of liver cirrhosis, HCC, and mortality at 3 and 5 years was 10.9% and 21.3%, respectively. The independent factors related to the composite disease progression were age \( \geq 55 \) years, platelet counts \(<150 \times 10^9/\text{L}\), and failure to achieve SVR. Antiviral treatment, mainly PR therapy, was undertaken in 237 patients (62.0%), and SVR was achieved in 168 patients among the 237 treated patients (74.3%). The treated group was younger and had a lower range of FIB-4 index than the nontreated group. Interestingly, the SVR group showed the best outcome compared with both the non-SVR group and the treatment-naive group.

HCC is a major clinical outcome of chronic HCV infection. A posttransfusion chronic hepatitis C cohort from Japan \((n=469)\) followed from 1989 to 2000 showed a HCC development rate of 11% during a mean 7.7 years of observation (5-year cumulative probability of HCC development, 5.2%).\(^\text{[10]}\) Among them, 145 patients received interferon therapy and 42 patients (29%) achieved sustained virologic response. In the recent study of the Veterans Affairs (VA) clinical registry of the United States from 1999 to 2010, the cumulative probability of HCC development was 3.5% at a mean postindex period of 6.1 years in HCV-infected veterans \((n=128,481)\).\(^\text{[12]}\) Among them, 24.3% of patients underwent antiviral treatment, and 16.4% of treated patients achieved an undetectable viral load. Our results showed that the cumulative probability of HCC development at 3 and 5 years was 1.6% and

| Table 3 |
| --- |
| Univariate and multivariate analysis of factors associated with the composite disease progression (development of cirrhosis, HCC, or mortality). |
| Variable | Univariate analysis\(^\dagger\) | Multivariate analysis\(^\dagger\) |
| --- | --- | --- |
| Age at entry, y | HR (95% CI) | \( P \) value | HR (95% CI) | \( P \) value |
| <55 | 3.712 (1.938–7.109) | 0.001\(^\ast\) | 2.924 (1.218–7.021) | 0.016\(^\ast\) |
| \( \geq 55 \) | | | |
| Gender | | | |
| Female | 1.437 (0.825–2.504) | 0.200 | |
| Male | | | |
| BMI | | | |
| <25 kg/m\(^2\) | 1.718 (0.962–3.069) | 1.718 | |
| \( \geq 25 \) kg/m\(^2\) | | | |
| Employed state | | | |
| Employed | 2.267 (1.187–4.330) | 0.013\(^\ast\) | |
| Unemployed | | | |
| Alcohol intake | | | |
| No or former | 0.874 (0.459–1.663) | 0.682 | |
| Current | | | |
| Smoking | | | |
| No or former | 0.740 (0.379–1.447) | 0.379 | |
| Yes | | | |
| Diabetes | | | |
| No | 2.281 (1.214–2.924) | 0.379 | |
| Yes | | | |
| Albumin | | | |
| <3.5 g/dL | 0.208 (0.064–0.676) | <0.009\(^\ast\) | |
| \( \geq 3.5 \) g/dL | | | |
| GGT | | | |
| <70 IU/L | 0.809 (0.490–1.391) | 0.049\(^\ast\) | |
| \( \geq 70 \) IU/L | | | |
| Platelet | | | |
| <150 \( \times 10^9/\text{L} \) | 0.197 (0.108–0.358) | <0.001\(^\ast\) | 0.313 (0.134–0.733) | 0.007\(^\ast\) |
| \( \geq 150 \) \( \times 10^9/\text{L} \) | | | |
| SVR | | | |
| (+) | 0.233 (0.103–0.525) | <0.001\(^\ast\) | 0.254 (0.108–0.593) | 0.002\(^\ast\) |
| (-) | | | |
| FIB-4 index | | | |
| <1.45 | 38.35 (2.982–506.26) | 0.005\(^\ast\) | | |
| \( \geq 1.45 \) | | | |

\( P \) values are for the comparison between groups. BMI = body mass index, FIB-4 index = fibrosis-4 index, GGT = gamma glutamyl transerase, SVR = sustained virologic response.

\(^\ast\) \( P < 0.05. \)

\(^\dagger\) According to the Cox proportional hazard model.
4.5%, respectively. Considering the high treatment rate and high SVR rate of this study, HCC development seems to be higher than in the US study, but similar to or rather higher than the remote Japanese posttransfusion cohort results. Though the study populations were heterogeneous, and study methods differed greatly from studies on the clinical outcomes of chronic hepatitis C, Korean patients seem to be at higher risk of HCC development than Caucasian patients, due to unknown reasons. The independent factors related to HCC development were lower albumin level and non-SVR in this study, which reflects advanced fibrosis and no viral eradication, respectively.

This study demonstrated that the cumulative probability of overall survival was 99.7% and 96% at 3 and 5 years and the estimated incidence rate of overall mortality was 3.0 (95% CI, 1.1–7.9) per 1000 person-years. Among 4 cases of mortality (1.0%) during the follow-up period, only 1 liver-related death due to HCC progression was observed. Therefore, almost all of the chronic hepatitis C patients did not die due to liver problems within about 5 years of observation. A community-based prospective cohort study from Taiwan reported that 677 HCV RNA-positive people showed significantly higher cumulative probability of all-cause mortality (30.1%) and liver cancer mortality (10.4%) at 18 years of observation than in 298 anti-HCV positive but HCV RNA negative people (12.8% and 1.6%, respectively). The German HCV 1b contaminated anti-D cohort study at 35 years of follow-up (n=718) showed that cirrhosis developed in 9.3% of the overall cohort, with higher incidence in the non-SVR group (15.3%) and treatment naive patients (14.2%) than the SVR group (6%). In the German cohort, including 189 spontaneously recovered HCV infections, 4.2% of patients died (n=30), and cirrhosis-related death was observed in 17 patients. However, the recent VA registry study (n=128,769) showed mortality of 12.0% at a mean postindex period of 6.1 years, which seems to be higher than our results, though the cause of death was not reported in that study. As indicated in the Taiwan, German, and VA registry studies, the clinical outcomes of chronic hepatitis C were quite variable according the study populations, observational period, or method, resulting in difficulty in making a direct comparison of those studies.

A large variety of environmental and host factors related to the disease progression were reported such as age, gender, duration of infection, age at infection, host interleukin 28B polymorphism, alcohol intake, obesity, diabetes, coinfection with hepatitis B virus, or human immunodeficiency virus antiviral treatment or SVR. Despite significant heterogeneity, patient’s age, fibrosis degree, and SVR were the most commonly reported predictors for disease progression. In this study, the independent factors related to the composite disease progression were age ≥55 years, platelet counts <150 × 10^9/L, and failure to achieve SVR, which were compatible with the previous results. Interestingly, treatment naive patients showed a poor outcome, similar to that of the non-SVR group, compared with the SVR group. The treatment naive group showed older age, lower employment rate, and higher FIB-4 index, suggesting a large proportion of unmet needs for interferon-based therapy.

FIB-4 index was a simple, accurate, and inexpensive method for assessing liver fibrosis in HCV infection, as was demonstrated by the fact that liver biopsy could be avoided in 71% of HIV/HCV coinfection using the FIB-4 index. According to the changing speed of the FIB-4 index, as indicated by ΔFIB-4 index/yr with a cutoff level of 0.5, the disease progression rates were significantly different. Therefore, during patient follow-up, calculation of ΔFIB-4/yr is meaningful to assess disease progression rate.

Compared with the outcomes of HCV-related liver disease, chronic hepatitis B in Korea resulted in the development of liver cirrhosis at a rate of 5.1% per year (5-year cumulative probability of 23%) and of HCC with 0.8% per year (5-year cumulative probability of 3%). The epidemiology of HBV infection and patient demographics of HBV-infected patients are significantly different from those of HCV-infected patients, but the outcomes and liver disease progression rates seem to be not so different. However, due to the intrinsically different characteristics of HBV and HCV disease, head-to-head comparison is of moot value. There are several limitations of this study. Compared to Western data, the sample size is small, information on alcohol intake and smoking reflected only a 1-year period at enrollment rather than lifetime exposure, the infection period was not known in most of the patients, and follow-up duration was relatively short. However, this is a prospective, multicenter cohort study maintained in a systematic way in real-world practice in HBV endemic Asian chronic hepatitis C patients with extensive clinical data and detailed analysis. This study can provide baseline data...
of additional effects of DAA therapy on the clinical outcomes of chronic hepatitis C in the future.

In conclusion, the clinical outcomes of chronic hepatitis C patients in South Korea were modest but significant with the cumulative probability of development of HCC, and all-cause mortality at 5 years was 4.5% and 4%, respectively. In spite of the relatively high rate of interferon-based antiviral treatment and the high SVR rate, patients with old age, low platelet count, and treatment-naïve or nonachievement of SVR should be carefully monitored for disease progression. In these cases, DAA therapy is a top priority.

Acknowledgments

The authors are grateful to their research coordinators (Da Seul Lee, Da Woon Jeong, Ye Young Lee, Sun Mi Kim, Hye Young Kang, Jeong-Wol Moon, Hui Bang, Young Soon Kim, Hyun Mi Kim, and Hyen Ji Yoon), and research supporting team in Kang, Jeong-Wol Moon, Hui Bang, Young Soon Kim, Hyun Mi Lee, Da Woon Jeong, Ye Young Lee, Sun Mi Kim, Hyo Young Lee. References

[1] Mohd Hanaﬁah K, Groeger J, Flaxman AD, et al. Global epidemiology of hepatitis C virus infection: new estimates of age-speciﬁc antibody to HCV seroprevalence. Hepatology 2013;57:1333–42.

[2] The Korean Association for the Study of the Liver (KASL)KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol 2016;22:76–139.

[3] Kim do Y, Kim IH, Jeong SH, et al. A nationwide seroepidemiology of hepatitis C virus infection in South Korea. Liver Int 2013;33:586–94.

[4] Seef LB. The history of the “natural history” of hepatitis C (1968–2009). Liver Int 2009;29(suppl 1):89–99.

[5] Then HH, Yi Q, Dore GJ, et al. Estimation of stage-speciﬁc ﬁbrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 2008;48:418–31.

[6] Global Burden of Hepatitis C.W.GGlobal burden of disease (GBD) for hepatitis C. J Clin Pharmacol 2004;44:20–9.

[7] Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975–82.

[8] Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346–55.

[9] Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001;358:958–65.

[10] Hamada H, Yamasaki H, Yano K, et al. Impact of aging on the development of hepatocellular carcinoma in patients with posttransfusion chronic hepatitis C. Cancer 2002;95:331–9.

[11] Lee MH, Yang HJ, Lu SN, et al. Hepatitis C virus genotype 1b increases cumulative lifetime risk of hepatocellular carcinoma. Int J Cancer 2014;135:1119–26.

[12] McComb J, Matsuda T, Tonnou-Mihara I, et al. The risk of long-term morbidity and mortality in patients with chronic hepatitis C: results from an analysis of data from a Department of Veterans Affairs Clinical Registry. JAMA Intern Med 2014;174:204–12.

[13] Simon DH, Park SW, Kang P, et al. Disease progression and the risk factor analysis for chronic hepatitis C. Liver Int 2008;28:1363–9.

[14] Wiese M, Fischer J, Lobermann M, et al. Evaluation of liver disease progression in the German hepatitis C virus (1b)-contaminated anti-D cohort at 35 years after infection. Hepatology 2014;59:49–57.

[15] Deuflice-Burban S, Detelene P, Buti M, et al. Predicted effects of treatment for HCV infection vary among European countries. Gastroenterology 2012;143:974–85.

[16] Lee MH, Yang HJ, Lu SN, et al. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis 2012;206:469–77.

[17] Ly KN, Xing J, Klevens RM, et al. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med 2012;156:271–8.

[18] The Korean Association for the Study of the Liver (KASL)KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol 2014;20:89–136.

[19] Seong MH, Kih H, Kim YS, et al. Clinical and epidemiological features of hepatitis C virus infection in South Korea: a prospective, multicenter cohort study. J Med Virol 2013;85:1724–33.

[20] Balducci L, Extermann M. Management of cancer in the older person: a practical approach. Oncologist 2000;5:224–37.

[21] Cusi K. The relationship between hepatitis C virus infection and diabetes: time for a divorce? Hepatology 2014;60:1121–3.

[22] Goukassian D, Gad F, Yaar M, et al. Mechanisms and implications of the age-associated decrease in DNA repair capacity. FASEB J 2000;14:1325–37.

[23] Massaia SB, Ostrowski M, Heathcoe EJ. Disease progression in chronic hepatitis C: modifiable and nonmodifiable factors. Gastroenterology 2008;134:1699–714.

[24] Uto H, Stuver SO, Hayashi K, et al. Increased rate of death related to progression chronic hepatitis C. Cancer 2002;95:331–9.

[25] McMahon BJ. Natural history of chronic hepatitis B. Clin Liver Dis 2010;14:381–96.